With the increasing prevalence of various types of fungal infections, the market for dermatophytosis treatment is observing a strong growth across the world. Dermatophytosis is caused by a fungus, called dermatophytes, which belongs to a family of organisms that can easily break down the keratin in nails, epidermis, hooves and horns, and epidermis. Dermatophytosis generally develops through direct contact with infected wounds and infected shoes, towels, or shower stalls. Drug makers are actively working on developing a highly efficient treatment for this fungus infection.
In this blog post, researchers at TMR Research are answering some of the important queries regarding the global dermatophytosis treatment market:
What are the key factors that are influencing the global market for dermatophytosis treatment?
The increasing population base of individuals with weak immune systems is the main factor behind the growth of the global dermatophytosis treatment market. Since the immune system weakens with age, the constantly increasing geriatric population has surfaced as the key contributor to this market. Apart from this, the rising sedentary lifestyle and the augmenting prevalence of hospital-acquired infections (HAIs) are also resulting in a higher rate of dermatophytosis, driving the demand for dermatophytosis treatment.
On the flip side, the dearth of awareness regarding dermatophytosis and several related diseases and their treatment options may limit the growth prospects of this market in the near future. The reluctance among patients in going for the treatment of dermatophytosis may also hamper the growth of this market, worldwide, over the next few years.
Get Sample Copy of this Report @
Which of the regional markets is likely to dominate the worldwide dermatophytosis treatment market?
Presently, North America is dominating the global market for dermatophytosis treatment, with Europe trailing closely. Availability of favorable reimbursement coverage, presence of immensely developed healthcare infrastructure, greater healthcare spending, higher awareness among people regarding dermatophytosis and the benefits of early diagnosis and treatment, and the ample availability of advanced healthcare facilities are the main factors that has been supporting the markets for dermatophytosis treatment in North America and Europe. Both the regional markets are likely to remain on the top over the next few years.
Which are the most popular strategies that players are adopting in the global market?
Novartis, Quinnova Pharmaceuticals, Tinea Pharmaceuticals, Sun Pharmaceuticals, NB Therapeutics, Valeant Pharmaceuticals, AmDerma Pharmaceuticals, Merz Pharma, and Perrigo are some of the leading players in the global market for dermatophytosis treatment. These players are aggressively focused towards offering advanced and highly effective treatment options for dermatophytosis. They are likely to get increasingly involved into strategic collaborations, specifically mergers and acquisitions to strengthen their position in this market.